Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 61

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 61
---
, primarily due to increase in notes payable offset by increase in accounts receivable.

Liquidity and Capital Resources

|                                                      |     |    Year Ended |          |   |     |      |          |   |
|:-----------------------------------------------------|:----|--------------:|---------:|:--|:----|-----:|---------:|:--|
|                                                      |     | September 30, |          |   |     |      |          |   |
|                                                      |     |          2024 |          |   |     | 2023 |          |   |
| Net cash used in operating activities                |     |             $ | (751,536 | ) |     |    $ | (173,917 | ) |
| Net cash provided by financing activities            |     |               |  631,215 |   |     |      |  243,750 |   |
| Net increase (decrease) in cash and cash equivalents |     |             $ | (120,321 | ) |     |    $ |   69,833 |   |
| Cash, beginning of year                              |     |               |  121,037 |   |     |      |   51,204 |   |
| Cash, end of year                                    |     |             $ |      716 |   |     |    $ |  121,037 |   |

Operating Activities

Net cash used in operating activities for the year ended September 30, 2024 was $751,536, compared to $173,917, for the year ended September 30, 2023, an increase of $577,619. The increase in cash used in operating activities is primarily attributable to increases in accounts receivables and prepaids. Net cash used in operating activity also includes impact of Unrealized Loss on Investment Securities of $ 204,847 and adjustment of Unearned Income.

Financing Activities

Net cash generated by financing activities for the year ended September 30, 2024 was $631,215 which consisted of proceeds from notes payables and common stock issued for cash.

<div align='center'>44</div>

Liquidity & Capital Resources Outlook

As of September 30, 2024, the Company had cash of $ 716 and net working capital of ($5,235,105)

The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has incurred and expects to continue incur significant research &